Literature DB >> 25294377

Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population.

Xin-yan Yu1, Yi Zhao, Xiao-xiao Song, Zhen-ya Song.   

Abstract

BACKGROUND AND
OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is associated with arterial stiffness in the general population. Age, obesity, hypertension, and diabetics are risk factors for arterial stiffness. In this study, we aimed to investigate the association between NAFLD and arterial stiffness as measured by brachial-ankle pulse wave velocity (baPWV) in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population.
METHODS: A cross-sectional study with 1296 non-obese, non-hypertensive, and non-diabetic young and middle-aged (20-65 years) subjects undergoing routine medical check-ups in the International Health Care Center of the Second Affiliated Hospital of School of Medicine of Zhejiang University was carried out. Fatty liver was diagnosed by ultrasonography, and baPWV was measured using an automatic waveform analyzer. The subjects were classified into two groups according to the presence of NAFLD, and divided into a further two groups according to their baPWV.
RESULTS: The overall incidence of NAFLD was 19.0%, and NAFLD patients had a significantly higher level of baPWV than the controls ((1321±158) cm/s vs. (1244±154) cm/s; P<0.001). The incidence of NAFLD was clearly higher in the increased baPWV group than in the normal baPWV group (29.3% vs. 16.9%; P<0.001), and the incidence increased in line with the increase of baPWV quartiles in the normal range as well as with the severity of arterial stiffness (both P for trend <0.001). Multiple linear logistic regression analysis showed that the presence of NAFLD was positively and independently associated with baPWV.
CONCLUSIONS: Our results suggest that the presence of NAFLD is associated with arterial stiffness as measured by baPWV in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population.

Entities:  

Keywords:  Arterial stiffness; Brachial-ankle pulse wave velocity; Non-alcoholic fatty liver disease; Risk factor

Mesh:

Year:  2014        PMID: 25294377      PMCID: PMC4201316          DOI: 10.1631/jzus.B1400028

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  45 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 2.  Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.

Authors:  Giovanni Targher; Guido Arcaro
Journal:  Atherosclerosis       Date:  2006-09-12       Impact factor: 5.162

3.  Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Roberto Tessari; Luciano Zenari; Giuseppe Lippi; Guido Arcaro
Journal:  Diabetes Care       Date:  2007-05-22       Impact factor: 19.112

4.  Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.

Authors:  Teoman Dogru; Cemal Nuri Ercin; Gokhan Erdem; Alper Sonmez; Serkan Tapan; Ilker Tasci
Journal:  Am J Gastroenterol       Date:  2008-12       Impact factor: 10.864

5.  Increased C-reactive protein is associated with future development of diabetes mellitus in essential hypertensive patients.

Authors:  Chiung-Mei Weng; Chang-Hua Chou; Yao-Yi Huang; Chih-Chan Lin; Yen-Wen Liu; Wei-Chuan Tsai
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 6.  GI epidemiology: nonalcoholic fatty liver disease.

Authors:  P Angulo
Journal:  Aliment Pharmacol Ther       Date:  2007-04-15       Impact factor: 8.171

7.  High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population.

Authors:  Tomomi Kogiso; Yuriko Moriyoshi; Satoru Shimizu; Hikaru Nagahara; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2009-03-07       Impact factor: 7.527

8.  In addition to insulin resistance and obesity, brachial-ankle pulse wave velocity is strongly associated with metabolic syndrome in Chinese--a population-based study (Taichung Community Health Study, TCHS).

Authors:  Wen-Yuan Lin; Ming-May Lai; Chia-Ing Li; Cheng-Chieh Lin; Tsai-Chung Li; Ching-Chu Chen; Tsann Lin; Chiu-Shong Liu
Journal:  J Atheroscler Thromb       Date:  2009-04-30       Impact factor: 4.928

9.  Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.

Authors:  Winston Dunn; Ronghui Xu; Deborah L Wingard; Christopher Rogers; Paul Angulo; Zobair M Younossi; Jeffrey B Schwimmer
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

10.  Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Cristián Cerda; Rosa María Pérez-Ayuso; Arnoldo Riquelme; Alejandro Soza; Paulina Villaseca; Teresa Sir-Petermann; Manuel Espinoza; Margarita Pizarro; Nancy Solis; Juan Francisco Miquel; Marco Arrese
Journal:  J Hepatol       Date:  2007-05-24       Impact factor: 25.083

View more
  9 in total

1.  Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia.

Authors:  Jing Zhao; Hui-min Yan; Ya Li; Jia Wang; Lu Han; Zhi-hao Wang; Meng-xiong Tang; Wei Zhang; Yun Zhang; Ming Zhong
Journal:  J Zhejiang Univ Sci B       Date:  2015-05       Impact factor: 3.066

Review 2.  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Niki Katsiki; Michael Doumas; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

3.  Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index.

Authors:  Goh Eun Chung; Su-Yeon Choi; Donghee Kim; Min-Sun Kwak; Hyo Eun Park; Min-Kyung Kim; Jeong Yoon Yim
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

Review 4.  NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms?

Authors:  Cristiane A Villela-Nogueira; Nathalie C Leite; Claudia R L Cardoso; Gil F Salles
Journal:  Int J Mol Sci       Date:  2016-04-20       Impact factor: 5.923

5.  Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis.

Authors:  Rahul Sao; Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2017-07-05       Impact factor: 3.318

6.  Nonalcoholic Fatty Liver Disease and Coronary Artery Disease: Big Brothers in Patients with Acute Coronary Syndrome.

Authors:  Mauricio Montemezzo; Ahmed AlTurki; Fabio Stahlschmidt; Marcia Olandoski; Jean Rodrigo Tafarel; Dalton Bertolin Precoma
Journal:  ScientificWorldJournal       Date:  2020-04-13

7.  Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.

Authors:  Xin-Yan Yu; Xiao-Xiao Song; Yu-Ling Tong; Ling-Yan Wu; Zhen-Ya Song
Journal:  Medicine (Baltimore)       Date:  2020-11-25       Impact factor: 1.889

8.  Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.

Authors:  Lampros Chrysavgis; Eleftheria Ztriva; Adonis Protopapas; Konstantinos Tziomalos; Evangelos Cholongitas
Journal:  World J Gastroenterol       Date:  2020-11-14       Impact factor: 5.742

Review 9.  Non-alcoholic fatty liver disease-From the cardiologist perspective.

Authors:  Oana Sîrbu; Mariana Floria; Petru Dăscălița; Victorița Şorodoc; Laurențiu Şorodoc
Journal:  Anatol J Cardiol       Date:  2016-07       Impact factor: 1.596

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.